The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Open accessAbstract
Background Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal tract. The standard treatment of localized, primary GIST has been surgical resection alone. Most GISTs have a mutation in the KIT proto-oncogene, or less commonly in platelet-derived growth factor receptor alpha (PDGFRα). Imatinib mesylate is a small molecule that inhibits activation of the KIT and PDGFRα proteins and is effective in metastatic GIST. We hypothesized that adjuvant treatment with imatinib would result in improved recurrence-free survival (RFS) compared to placebo treatment following resection of localized, primary GIST. Methods We performed a randomized phase 3, double-blind, placebo-controlled, multicenter trial. Eligible patients had complete gross resection of a primary GIST at least 3 cm in size that stained positive for KIT protein. Patients were randomly assigned to receive imatinib 400 mg/day or placebo daily for one year following surgical resection. Patients assigned to placebo were eligible to crossover to imatinib treatment in the event of tumor recurrence. The primary endpoint was RFS and intention to treat analysis was performed. This study is registered at ClinicalTrials.gov, number NCT00041197. Findings From July 2002 to April 2007, 359 patients were randomized to imatinib and 354 to placebo. Accrual was stopped early based on the results of a planned interim analysis. Imatinib significantly prolonged RFS compared with placebo (98% vs. 83% at 1 year; overall hazard ratio 0.35; one-sided p<0.0001). Overall survival (OS) was similar (99.2% vs. 99.7% at 1 year; hazard ratio 0.66; p=0.47). Adjuvant imatinib was well-tolerated with a low rate of serious adverse events. Interpretation Adjuvant imatinib therapy is safe and compared to placebo treatment appears to prolong RFS following the resection of primary GIST. OS is not different at this time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Self-citation
Cited by
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
Motzer, R. J., Jonasch, E., Michaelson, M. D., Nandagopal, L., Gore, J. L., George, S., Alva, A., Haas, N., Harrison, M. R., Plimack, E. R., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0054 · Cited by 287
(2012) · Annals of Oncology · doi:10.1093/annonc/mds252 · Cited by 281
Jeong, W., Doroshow, J. H., & Kummar, S. (2013) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2013.06.001 · Cited by 59
Toward a More Precise Future for Oncology
Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.014 · Cited by 48
Metadata
- Authors
- DeMatteo, R. P., Ballman, K. V., Antonescu, C. R., Maki, R. G., Pisters, P. W., Demetri, G. D., Blackstein, M. E., Blanke, C. D., von Mehren, M., Brennan, M. F., Patel, S., McCarter, M. D., Polikoff, J. A., Tan, B. R., & Owzar, K.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 373
- Issue
- 9669
- Pages
- 1097-1104
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2165837347
- Cited by
- 1,369
- References
- 1
- FWCI
- 118.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(09)60500-6
- The paper
- DeMatteo, R. P., Ballman, K. V., Antonescu, C. R., Maki, R. G., Pisters, P. W., Demetri, G. D., Blackstein, M. E., Blanke, C. D., von Mehren, M., Brennan, M. F., Patel, S., McCarter, M. D., Polikoff, J. A., Tan, B. R., & Owzar, K. (2009). Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(09)60500-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
